21st International Congress » Clinical Trials and Therapy in Movement Disorders

1:15pm-2:45pm

A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations

S. Ramaswamy, W. Wen, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

1:15pm-2:45pm

A Phase 2, Open-Label, Dose-Escalating Study to Evaluate the Safety and Preliminary Efficacy of Daxibotulinumtoxina for Injection (RT002) in Isolated Cervical Dystonia

C. Comella, J. Jankovic, D. Truong, A. Brashear, A. Patel, M. Evatt, C. Chung, R. Rubio (Chicago, IL, USA)

1:15pm-2:45pm

A randomised control trial to investigate if people with Parkinson’s disease can exercise at high intensity, and does this improve their cardiorespiratory function? A feasibility study

M. Harvey, R. Walker, W. Gray, K. Weston, L. Oates (North Shields, United Kingdom)

1:15pm-2:45pm

A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome

D. Gilbert, T. Murphy, J. Jankovic, C. Budman, K. Black, R. Kurlan, K. Coffman, J. McCracken, J. Juncos, J. Grant, R. Chipkin (Cincinnati, OH, USA)

1:15pm-2:45pm

Aquatic Dual Task Exercise: Effects on Body Balance of Individuals with Parkinson’s Disease

A. Silva, V. Israel (Curitiba, Brazil)

1:15pm-2:45pm

Are the exergaming effective for improving functional exercise capacity, and quality of life in Patients with Parkinson’s Disease?

C. Gemin, L. da Silva, M. Ribas Correa, H. Ghizone Teive, S. Valderramas (curitiba, Brazil)

1:15pm-2:45pm

Association of vitamin D deficiency in Parkinson disease

A. MUJTABA, N. ALSOMALI, A. ALSHAMRANI, S. MARAR, T. Alayan, J. BAJWA (RIYADH, Saudi Arabia)

1:15pm-2:45pm

Basal Ganglia Circuits for Motor and Behavioral, Emotional Performances

F. Fujiyama (Kyotanabe, Japan)

1:15pm-2:45pm

Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results

S. Kymes, C. François, G. Peng, G. Rowse, S. Isaacson (Deerfield, IL, USA)

1:15pm-2:45pm

Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia

M. Lew, D. Snyder (Los Angeles, CA, USA)

1:15pm-2:45pm

Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial

M. Jog, J. Lee, M. Althaus, A. Scheschonka, H. Dersch, E.T. Study Team, D. Simpson (London, ON, Canada)

1:15pm-2:45pm

Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)

R. Hauser, R. Pahwa, C. Tanner, W. Oertel, S. Isaacson, M.J. Stempien, L. Felt, R. Johnson (Tampa, FL, USA)

1:15pm-2:45pm

Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.

N. Malek, M. Lawton, K. Grosset, N. Bajaj, R. Barker, Y. Ben-Shlomo, D. Burn, T. Foltynie, J. Hardy, H. Morris, N. Williams, N. Wood, D. Grosset (Ipswich, United Kingdom)

1:15pm-2:45pm

Long-term effect of botulinum toxin injection in the external oblique muscle to treat camptocormia in three patients with Parkinson’s disease.

H. Todo (Sanda, Japan)

1:15pm-2:45pm

MitoQ and Reduced Glutathione Protects Against Dopamine Induced Brain Mitochondrial Electron Transport Chain Inhibition During Extended In Vitro Incubation: Involvement of Free Radicals and Quinone Products

A. MAITI (Bengaluru, India)

1:15pm-2:45pm

Motor and Body Composition Variables by Parkinson’s Disease Staging

L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

1:15pm-2:45pm

Parkinsonics – A Prospective, Randomized, Blinded, Cross-Over Trial of Group Singing for Motor and Non-Motor Symptoms in Idiopathic Parkinson Disease (PD)

A. Butala, A. Swaminathan, S. Dunlop, Y. Salnikova, B. Ficek, B. Portnoff, M. Harper, B. Vernon, Z. Mari, A. Pantelyat (Baltimore, MD, USA)

1:15pm-2:45pm

Physical Mobility Predictors and the Bone Health in Parkinson’s Disease

L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

1:15pm-2:45pm

Postural control is maintained after a 8-months period of exercise in people with Parkinson’s disease

L. Gobbi, N. Rinaldi, P. Pelicioni, E. Lirani-Silva, L. Moraes, M. Pereira (Rio Claro, Brazil)

1:15pm-2:45pm

PROMESA: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach – evaluation of serious adverse events

M. Schuberth, J. Levin, S. Maaß, G. Respondek, K. Bötzel, G. Höglinger (Muenchen, Germany)

1:15pm-2:45pm

Rationale and Design of a Phase 2 Study to Evaluate the Efficacy of Intepirdine (RVT-101) in Improving Gait and Balance in Patients with Dementia

S. Ramaswamy, N. Bohnen, M. Muller, I. Lombardo, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

1:15pm-2:45pm

Rehabilitation program with or without a whey protein-based nutritional support enriched with essential aminoacids and vitamin D in patients with Parkinson’s disease or parkinsonism: study design of a randomized, controlled trial.

m. barichella, E. Cereda, G. Pinelli, l. Iorio, V. Ferri, g. Frazzitta, E. Cassani, G. Riboldazzi, G. Pezzoli (Milano, Italy)

1:15pm-2:45pm

WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)